2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1578 Dissecting AYA outcomes in acute myeloid leukemia: Patient characteristics, mutational landscape and comparative outcomes

Parisa Abedi, MD, Luca Lanino, MD2, Rohan K Achar, MD, MSCR3, Henry Dumke, MD4, Razan Mansour, MD5, Nurefsan Sariipek, MD6, Benjamin Rolles, MD7, Abdulrahman Alhajahjeh, MD8, Jan Philipp Bewersdorf, MD9, Luis E. Aguirre, MD, MPH10, Nikolai Podoltsev, MD, PhD11, Lourdes Mendez, MD12, Alain Mina, MD13, Amer M. Zeidan, MD14, Maximilian Stahl, MD15
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 Yale School of Medicine, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States
7 Yale School of Medicine, New Haven, Connecticut, United States
8 Yale School of Medicine, New Haven, Connecticut, United States
9 Yale School of Medicine, New Haven, Connecticut, United States
10 Yale School of Medicine, New Haven, Connecticut, United States
11 Yale School of Medicine, New Haven, Connecticut, United States
12 Yale School of Medicine, New Haven, Connecticut, United States
13 Yale School of Medicine, New Haven, Connecticut, United States
14 Yale School of Medicine, New Haven, Connecticut, United States
15 Yale School of Medicine, New Haven, Connecticut, United States

Background: While cancer in adolescents and young adults (AYA, ages 18–39) is increasingly recognized as a clinical challenge, acute myeloid leukemia (AML) in this population remains understudied. Hence, we used a large real-world dataset with paired clinical, and mutational data to characterize demographics, disease features, treatment patterns, and outcomes in AYA AML, benchmarking against middle-aged (40–60) and older (>60) adults.

Methods: We analyzed 12,283 patients (pts) with newly diagnosed AML (AYA: n=961; 40–60: n=2,381; >60: n=8,941) from the Flatiron Health Research Database. AYA subgroups (adolescents (18–24): n=197 vs. young adults (25–39): n=794) were also evaluated. Ontogeny was assigned hierarchically (TP53 > secondary > de novo) and disease risk by ELN 2022. Continuous age effects were modeled via restricted cubic splines.

Results: AYA pts presented with distinct baseline demographic characteristics, enriched favorable genomic features, and lower frequencies of high-risk disease. AYA pts were more frequently female (53.3% vs 49.5% [40–60] vs 41.0% [>60]), non-White (33.5% vs 28.9% vs 19.4%), Hispanic/Latino (15.9% vs 11.0% vs 4.6%), and Medicaid-insured (10.1% vs 6.6% vs 1.9%; all p<0.001). Disease features also diverged markedly: AYA cases were predominantly de novo (92.8% vs 79.0% and 53.6%), with lower rates of TP53 mutations (2.6% vs 7.4% and 12.1%) and ELN Adverse risk (9.1% vs 14.9% and 20.4%). Genetically, the AYA mutational landscape was enriched for FLT3-ITD (23.4% vs 22.8% vs 12.8%), FLT3-TKD (12.2% vs 9.9% vs 5.2%), and CEBPA (9.1% vs 6.1% vs 5.8%), but depleted of TET2 (5.3% vs 8.5% vs 18.1%) and RUNX1 (7.8% vs 9.5% vs 15.0%; all p<0.001).

Frontline intensive chemotherapy predominated in AYA and 40–60 pts, whereas HMA-based therapy dominated in >60. Transplant was more common in AYA (38.6%) than in 40–60 (35.0%) or >60 (11.2%), and this age gap persisted within every ELN category.  Favorable 50.0% vs 47.3% vs 31.1%, Intermediate 54.8% vs 46.1% vs 27.8%, Adverse 52.8% vs 45.7% vs 35.1% (all p<0.004).

Within AYA, adolescents exhibited a higher prevalence of ELN Adverse risk (14.2% vs 7.9%, p=0.027) and RUNX1 mutations (13.1% vs 6.1%, p=0.002) compared to young adults. Ontogeny was similar between groups; no significant differences were observed in the rates of de novo AML (93.4% [95% CI 89.0–96.1] vs 92.7% [95% CI 90.6–94.3], p=0.72), secondary AML (4.1% [95% CI 2.1–7.8] vs 4.7% [95% CI 3.4–6.5], p=0.70), or TP53-mutated AML (2.5% [95% CI 1.1–5.8] vs 2.6% [95% CI 1.7–4.0], p=0.95).

Median OS was not reached in AYA or 40–60 and was 11.9 months (95% CI 11.3–12.4) in >60 (both  p<0.001 vs AYA). The 5-yr OS was 72.9% (95% CI 70.1–75.9) in AYA vs 55.9% (95% CI 53.9–58.0) in 40–60 and 25.0% (95% CI 24.0–25.9) in >60 year old pts (both p<0.001). Median OS was not reached in adolescents or young adults (log-rank p=0.16). When continuous age effects were modeled via restricted cubic splines, mortality risk remained flat into the mid-40s before rising continuously (1.24-fold at age 50, 1.79-fold at 60, and 2.39-fold at 70; p<0.001 for nonlinearity).

When evaluated across ELN risk categories, OS differences between AYA and ages 40–60 were not significant in Favorable risk, but were significant in Intermediate and Adverse risk, whereas all comparisons between AYA and ages >60 were highly significant. In favorable-risk disease, 5-year OS was 68.9% in AYA vs 62.4% at ages 40–60 (p=0.381) and 48.0% at >60 (p<0.001). In intermediate-risk disease, 5-year OS dropped from 61.8% in AYA to 49.9% at ages 40–60 and 28.1% at >60 (both p<0.001 vs AYA). In adverse-risk disease, 5-year OS fell from 66.4% in AYA to 42.3% at ages 40–60 (p=0.001) and 26.4% at >60 (p<0.001).

Conversely, 5-year overall OS was equivalent between adolescents and young adults in: favorable-risk (66.2% vs 69.5%, p=0.629), intermediate-risk (66.3% vs 60.8%, p=0.569), and adverse-risk (67.7% vs 65.9%, p=0.729).

Conclusions. AYA AML is defined by favorable disease biology and a persistent overall survival advantage compared with older adults. This survival gap between AYA and patients aged 40–60 is negated in ELN favorable-risk disease, whereas overall mortality risk accelerates continuously past the mid-40s rather than abruptly at age 60. Although overall survival remains equivalent across AYA subgroups, adolescents exhibit a marked enrichment for RUNX1mutations, potentially pointing to a higher underlying burden of germline RUNX1 predisposition.
Parisa Abedi, MD: No relevant conflicts of interest to declare.